[1]
|
A. Tefferi and D. G. Gilliland, “Oncogenes in Myeloproliferative Disorders,” Cell Cycle, Vol. 6, No. 5, 2007, pp. 550-566. doi:10.4161/cc.6.5.3919
|
[2]
|
C. R. Bartram, A. de Klein, A. Hagemeijer, T. van Agthoven, A. Geurts van Kessel, D. Bootsma, G. Grosveld, M. A. Ferguson-Smith, T. Davies, M. Stone, N. Heisterkamp, J. R. Stephenson and J. Groffen, “Translocation of C-Ab1 Oncogene Correlates with the presence of a Philadelphia Chromosome in Chronic Myelocytic Leukaemia,” Nature, Vol. 306, No. 5940, 1983, pp. 277-280.
doi:10.1038/306277a0
|
[3]
|
J. D. Rowley, “A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia Identified by Quinacrine Fluorescence and Giemsa Staining,” Nature, Vol. 243, 1973, pp. 290-293. doi:10.1038/243290a0
|
[4]
|
C. James, V. Ugo, J. P. Le Couedic, J. Staerk, F. Delhommeau, C. Lacout, L. Garcon, H. Raslova, R. Berger, A. Bennaceur-Griscelli, J. L. Villeval, S. N. Constantinescu, N. Casadevall and W. Vainchenker, “A Unique Clonal JAK2 Mutation Leading to Constitutive Signalling Causes Polycythaemia Vera,” Nature, Vol. 434, 2005, pp. 1144-1148. doi:10.1038/nature03546
|
[5]
|
R. L. Levine, M. Loriaux, B. J. Huntly, M. L. Loh, M. Beran, E. Stoffregen, R. Berger, J. J. Clark, S. G. Willis, K. T. Nguyen, N. J. Flores, E. Estey, N. Gattermann, S. Armstrong, A. T. Look, J. D. Griffin, O. A. Bernard, M. C. Heinrich, D. G. Gilliland, B. Druker and M. W. Deininger, “The JAK2V617F Activating Mutation Occurs in Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia, But Not in Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia,” Blood, Vol. 106, No. 10, 2005, pp. 3377-3379.
|
[6]
|
R. L. Levine, M. Wadleigh, J. Cools, B. L. Ebert, G. Wernig, B. J. Huntly, T. J. Boggon, I. Wlodarska, J. J. Clark, S. Moore, J. Adelsperger, S. Koo, J. C. Lee, S. Gabriel, T. Mercher, A. D’Andrea, S. Frohling, K. Dohner, P. Marynen, P. Vandenberghe, R. A. Mesa, A. Tefferi, J. D. Griffin, M. J. Eck, W. R. Sellers, M. Meyerson, T. R. Golub, S. J. Lee and D. G. Gilliland, “Activating Mutation in the Tyrosine Kinase JAK2 in Polycythemia Vera, Essential Thrombocythemia, and Myeloid Metaplasia with Myelofibrosis
|
[7]
|
I. Dalal, E. Arpaia, H. Dadi, S. Kulkarni, J. Squire and C. M. Roifman, “Cloning and Characterization of the Human Homolog of Mouse Jak2,” Blood, Vol. 91, No. 3, 1998, pp. 844-851.
|
[8]
|
E. Lippert, M. Boissinot, R. Kralovics, F. Girodon, I. Dobo, V. Praloran, N. Boiret-Dupre, R. C. Skoda and S. Hermouet, “The JAK2-V617F Mutation Is Frequently Present at Diagnosis in Patients with Essential Thrombocythemia and Polycythemia Vera,” Blood, Vol. 108, 2006, pp. 1865-1867. doi:10.1182/blood-2006-01-013540
|
[9]
|
F. Passamonti, E. Rumi, D. Pietra, M. G. Della Porta, E. Boveri, C. Pascutto, L. Vanelli, L. Arcaini, S. Burcheri, L. Malcovati, M. Lazzarino and M. Cazzola, “Relation between JAK2 (V617F) Mutation Status, Granulocyte Activation, and Constitutive Mobilization of CD34+ Cells into Peripheral Blood in Myeloproliferative Disorders,” Blood, Vol. 107, 2006, pp. 3676-3682.
doi:10.1182/blood-2005-09-3826
|
[10]
|
A. Tefferi, T. L. Lasho, S. M. Schwager, J. S. Strand, M. Elliott, R. Mesa, C. Y. Li, M. Wadleigh, S. J. Lee and D. G. Gilliland, “The Clinical Phenotype of Wild-Type, Heterozygous, and Homozygous JAK2V617F in Polycythemia Vera,” Cancer, Vol. 106, No. 3, 2006, pp. 631-635. doi:10.1002/cncr.21645
|
[11]
|
R. Tibes and R. A. Mesa, “Myeloproliferative Neoplasms 5 Years after Discovery of JAK2V617F: What Is the Impact of JAK2 Inhibitor Therapy?” Leukemia & lymphoma, Vol. 52, No. 7, 2011, pp. 1178-1187.
doi:10.3109/10428194.2011.566952
|
[12]
|
J. W. B. R. Vardiman and N. L. Harris, “WHO Histological Classification of Chronic Myeloproliferative Diseases,” In: H. Jaffees, H. Stein and J. W. Vardiman, Eds., World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues, 2001 Edition, International Agency for Research on Cancer (IARC) Press, Lyon, France, 2001, pp. 17-44.
|
[13]
|
World Medical Association General Assembly, “World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects,” Journal International de Bioethique International Journal of Bioethics, Vol. 15, No. 1, 2004, pp. 124-129.
|
[14]
|
J. Chasseriau, J. Rivet, F. Bilan, J. C. Chomel, F. Guilhot, N. Bourmeyster and A. Kitzis, “Characterization of the Different BCR-ABL Transcripts with a Single Multiplex RT-PCR,” The Journal of molecular diagnostics, Vol. 6, 2004, pp. 343-347. doi:10.1016/S1525-1578(10)60530-2
|
[15]
|
N. L. Harris, E. S. Jaffe, J. Diebold, G. Flandrin, H. K. Muller-Hermelink, J. Vardiman, T. A. Lister and C. D. Bloomfield, “The World Health Organization Classification of Neoplasms of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November, 1997,” The hematology journal, Vol. 1, No. 1, 2000, pp. 53-66.
doi:10.1038/sj.thj.6200013
|
[16]
|
C. James, V. Ugo, N. Casadevall, S. N. Constantinescu and W. Vainchenker, “A JAK2 Mutation in Myeloproliferative Disorders: Pathogenesis and Therapeutic and Scientific Prospects,” Trends in molecular medicine, Vol. 11, No. 12, 2005, pp. 546-554.
doi:10.1016/j.molmed.2005.10.003
|
[17]
|
R. Kralovics, F. Passamonti, A. S. Buser, S. S. Teo, R. Tiedt, J. R. Passweg, A. Tichelli, M. Cazzola and R. C. Skoda, “A Gain-Of-Function Mutation of JAK2 in Myeloproliferative Disorders,” The New England journal of medicine, Vol. 352, 2005, pp. 1779-1790.
doi:10.1056/NEJMoa051113
|
[18]
|
E. Kouroupi, K. Zoi, N. Parquet, C. Zoi, J. J. Kiladjian, V. Grigoraki, W. Vainchenker, F. Lellouche, C. Marzac, M. H. Schlageter, C. Dosquet, L. M. Scott, P. Fenaux, D. Loukopoulos, C. Chomienne and B. Cassinat, “Mutations in Exon 12 of JAK2 Are Mainly Found in JAK2 V617F-Negative Polycythaemia Vera Patients,” British Journal of Haematology, Vol. 142, 2008, pp. 676-679.
doi:10.1111/j.1365-2141.2008.07223.x
|
[19]
|
L. M. Scott, W. Tong, R. L. Levine, M. A. Scott, P. A. Beer, M. R. Stratton, P. A. Futreal, W. N. Erber, M. F. McMullin, C. N. Harrison, A. J. Warren, D. G. Gilliland, H. F. Lodish, A. R. Green, “JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis,” The New England Journal of Medicine, Vol. 356, 2007, pp. 459-468. doi:10.1056/NEJMoa065202
|
[20]
|
A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, R. Marchioli, et al., “Clinical Profile of Homozygous JAKV2 V617F Mutation in Patients with Polycythemia Vera or Essential Thrombocythemia,” Blood, Vol. 110, 2007, pp. 840-846.
doi:10.1182/blood-2006-12-064287
|